 |
|||
 |
 |
 |
|
Business Development
Contact Us
busdev@progenics.com
Collaborative Marketing and Development Agreements
Wyeth Pharmaceuticals (Wyeth)
In October 2009, Progenics and Wyeth Pharmaceuticals terminated their 2005 RELISTOR collaboration, as a result of which Progenics is regaining all worldwide rights to RELISTOR. Under their Transition Agreement, Wyeth is continuing to market and sell RELISTOR in the U.S. and elsewhere until approximately the end of 2010. Progenics is pursuing a range of strategic alternatives, including licensing, collaboration, strategic alliances and U.S. commercialization or co-promotion with its own sales force for RELISTOR at the end of this transition period.
In Japan, Progenics has licensed rights to the subcutaneous formulation of RELISTOR to Ono. Progenics is entitled to receive royalties and milestone payments from Ono for the development and commercialization of subcutaneous RELISTOR in Japan.
Licensing Agreements
Seattle Genetics, Inc.We have licensed Seattle Genetics, Inc. a proprietary antibody-drug conjugate (ADC) technology to link drugs to monoclonal antibodies that target PSMA.
We are responsible for research, product development, manufacturing and commercialization of all products, as well as milestones and royalty payments to Seattle Genetics.
AlphaVax Human VaccinesWe have licensed from AlphaVax Human Vaccines the alphavirus replicon vector technology system (a non-replicating viral vector system) for use in our viral vector vaccine.
We are responsible for milestones, maintenance fees, and royalty payments to AlphaVax Human Vaccines.